Company intelligence / Profile preview

Myocor

Minneapolis, Minnesota, United Statesmyocor.com ↗

Ownership: Private
Development stage: Clinical

Overview

Myocor developed and clinically evaluated less invasive medical devices to treat mitral valve insufficiency and heart failure. Its lead product, the Coapsys System, was designed to treat mild to severe mitral regurgitation via a closed-heart procedure. The company completed preclinical and early clinical studies and was initiating North American trials before being acquired.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Coapsys System

Clinical

Indications: Mitral valve insufficiency, Heart failure

Beyond the preview

Go deeper on Myocor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myocor.

Explore the full profile